AIFA Monitoring Registries for Managed Entry Agreements
Italy's national medicines agency (AIFA) uses a centralized registry system to monitor the use and performance of innovative medicines, especially those with uncertain clinical or economic benefits. These registries support managed entry agreements by tracking patient outcomes and treatment appropriateness, ensuring that medicines are used correctly and deliver value for money.
At a glance
Use when
Evaluating high-cost innovative medicines with uncertain clinical or economic benefits, particularly orphan drugs and those under managed entry agreements
Avoid when
When rapid, decentralized decision-making is required without centralized monitoring, or when real-world data collection infrastructure is unavailable
Inputs
Patient-level data from healthcare providers, medicine indication, regulatory status, type of managed entry agreement, clinical and economic uncertainty criteria
Outputs
Treatment authorization at patient level, aggregated real-world evidence, evaluation of treatment effectiveness and cost-effectiveness, recommendations for continued reimbursement
How it works
AIFA manages a national, web-based registry infrastructure funded by pharmaceutical companies but governed by the agency. The system supports managed entry agreements (MEAs) through three types of registries: appropriateness registries (monitoring correct use), financial-based agreements, and payment-by-result (outcomes-based) agreements. Data are collected at the patient level and used to inform reimbursement decisions, with analysis showing evolution over 15 years in response to regulatory and innovation assessment changes.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Organisational aspects
- Assumptions
- Accurate and timely data entry by healthcare providers; sustained funding and governance by AIFA; cooperation from pharmaceutical companies; ability to link patient outcomes with treatment exposure
- Strengths
- National coverage ensures consistency; centralized governance enhances data quality and comparability; supports both clinical and economic evaluation; enables outcomes-based reimbursement
- Limitations
- Limited use of accumulated data for broader healthcare optimization; decreasing number of outcomes-based agreements may reduce incentives for performance-based pricing; reliance on pharmaceutical industry funding may raise concerns about independence
- Also known as
- AIFA Registries, AIFA MEA Registries, AIFA Monitoring Registries
Questions this answers
- › How are innovative medicines monitored for appropriate use in Italy?
- › What types of managed entry agreements are supported by AIFA registries?
- › How are clinical and economic uncertainties addressed for orphan medicinal products?
- › What is the role of real-world data in reimbursement decisions?
- › How has the registry system evolved over time?
- › What is the split between cancer and non-cancer orphan medicinal products under monitoring?
References & sources
Similar by meaning
- AIFA innovativeness assessment algorithm (therapeutic innovativeness ranking)
- AIFA Guidelines for the economic evaluation of health technologies (P&R dossier, Chapter 9)
- Italian Group of Pharmacoeconomic Studies (GISP) guidelines for economic evaluations in Italy
- INFARMED Methodology for Pharmacotherapeutic Assessment of Health Technologies (METOD-AFT)
- Australian Managed Entry Scheme (MES)
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.